Clinical Trial

Functional Hypothalamic Activation in Response to Diazoxide

Study Description

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes as compared to non-diabetic individuals. This is important since people with diabetes have inappropriately high production of glucose, which could be at least in part due to impaired activation of important brain centers.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Diazoxide

Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.

Drug - Placebo

Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.

Additional Information

Official Study Title

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

Clinical Trial ID

NCT03566511

ParticipAid ID

QeZq5d